|
|
|
|
|
|
|
International Myositis Society - Newsletter 2/24
|
|
|
Dear iMyoS newsletter readers.
|
We hope you spent some merry and relaxing christmas days. The year 2024 is ending.
Many thanks to everyone who has supported iMyoS this year! We hope that you will continue to give us your attention in 2025.
|
We wish you and your families a healthy, happy new year!
|
|
|
|
GCOM 2026 - Save the date!
|
|
The 6th Global Conference on Myositis - GCOM will take place in Lisbon from 23-26 March 2026. All further information can be found on the iMyoS Lisbon Webpage
|
|
|
|
|
|
Upcoming papers on Myositis in press at our home journal "Clinical and Experimental Rheumatology - CER"
|
- Clinical features and prognosis of idiopathic inflammatory myopathies with coexistent multiple myositis-specific antibodies
X. Liang, J. Wu, H. Ren, M. Li, C. Huang, J. Guo, D. Li, J. Li, J. Zhu
- Pleural effusion as a predictor of rapidly progressive interstitial lung disease in idiopathic inflammatory myopathies associated with interstitial lung disease and mortality in idiopathic inflammatory myopathies
X. Liang, H. Ren, F. Xiao, S. Zheng, R. Wang, C. Huang, J. Guo, J. Li, J. Zhu
- Self-reported physical activity and fatigue and its associations to anxiety and depression in adult patients with idiopathic inflammatory myopathies: a MIHRA Psychological Impact and MIHRA Exercise and Rehabilitation Scientific Working Groups Collaboration
K.M. Andreasson, F.H. Espinosa-Ortega, H. Sandlund, H. Alexanderson
- CD44 is associated with muscle inflammation in polymyositis and skin injury in idiopathic inflammatory myopathy
Y. Zhou, Y. Zhao, G. Yin, L. Kang, X. Zhu, Q. Xie
- Human epididymis protein 4 (HE4) as a biomarker of interstitial lung disease in patients with idiopathic inflammatory myopathies
E. Zanatta, B. Moccaldi, A. Martini, L. Ienna, R. Depascale, M. Binda, M. Gatto, M. Zen, M. Tonello, A. Ghirardello, C. Giraudo, E. Balestro, M. Plebani, D. Basso, A. Doria, L. Iaccarino
- The clinical characteristics of pharyngeal and laryngeal lesions in anti-MDA5-positive dermatomyositis patients
W. Huang, F. Ren, D. Deng, L. Luo, J. Zhou, D. Huang, M. Tian, D. Chen, K. Qian, Y. Jiang, L. Tang
- Brepocitinib, a potent and selective TYK2/JAK1 inhibitor: scientific and clinical rationale for dermatomyositis
J.J. Paik, J. Vencovský, C. Charles-Schoeman, G. Wright, R.A. Vleugels, A.S. Goriounova, P.N. Mudd, R. Aggarwal
- Triple-combination therapy did not improve prognosis in anti-MDA5 positive dermatomyositis: a multi-centre longitudinal cohort study
H. You, C. Lv, L. Xu, L. Wang, T. Liu, F. Yuan, W. Yan, H. Wei, J. Wang, D. Meng, W. Tan
- Risk prediction modelling in idiopathic inflammatory myositis-associated interstitial lung disease based on seven factors including serum KL-6 and lung ultrasound B-lines
W. Zhang, G. Huang, S. Zheng, J. Lin, S. Hu, J. Zhuang, Z. Zhou, G. Du, K. Zheng, S. Chen, Q. Zhang, A. Mikish, A.-M. Hoffmann-Vold, M. Kuwana, M. Matucci-Cerinic, D.E. Furst, Y. Wang
- An update on myositis autoantibodies and insights into pathogenesis
G. Wang, N.J. McHugh
- Longitudinal assessment of disease activity and muscle strength in juvenile dermatomyositis: a multicentre registry study
D. Hortelan Antonio, B.O.L. Carneiro, T.A.P. Fernandes, A.M.Elias, A.J. Pantoja de Moraes, A.P. Vecchi, A. Cavalcanti, C.N. Rabelo Jr, C.M. Magalhaes, F.R. Sztajnbok, L.M. Carvalho, L.P. Marques, M.T. Terreri, M.M. Fraga, S.K.F. de Oliveira, S.B. Sacchetti, S. Appenzeller, T. Robazzi, V.P.L. Ferriani, C.A. Len, C.A.A. Silva, Claudia Saad-Magalhaes
- Cancer-associated myositis before and after the COVID-19 pandemic onset: comment
H. Daungsupawong, V. Wiwanitkit
- IL-16: a potential protective cytokine in idiopathic inflammatory myopathy
Y. Zhou, L. Kang, T. Liu, G. Yin, Q. Xie
- Successful management of pulmonary hypertension with baricitinib in a dermatomyositis patient
C. Rizzo, F. Camarda, L. La Barbera, G. Guggino
These myositis-related articles will appear at CER, and can be found there in the press section.
|
|
|
|
GCOM 2024
|
|
The 5th Global Conference on Myositis (GCOM 2024) was held in Pittsburgh (PA), USA on 13-16 March 2024 at the Wyndham Grand Pittsburgh. The abstract book, members of the steering, local & scientific committees and pictures are available at the iMyoS Pittsburgh Webpage
|
|
|
|
World Myositis Day 2024
|
|
This year, World Myositis Day was celebrated for the first time. Various international myositis groups and organizations organized different activities on this day to draw more attention to myositis. You can find all the activities planned and/or carried out here:
|
|
|
|
|
ERN ReCONNET Webinar
|
|
On the 25th of September 2024, the European Reference Network ERN - ReCONNET held a webinar on the topic: “Multidisciplinary diagnosis and team treatment in Idiopathic Inflammatory Myopathies” with Prof. Louise Diederichsen, Olga Drápalová and Silke Schlüter. The webinar was recorded and published on YouTube
|
|
|
|
General Assembly - 2024
|
The last iMyoS general assembly took place on the 3rd December 2024. After welcome by the iMyoS chairman - Jens Schmidt and the report of the treasurer - Silke Schlüter, there have been a election for a new auditor. Sabrina Zechel was suggested and elected for this position.
There was an update on GCOM 2026 and the subcommittees and cooperation partners reported on the current status of their work. You can find the iMyoS cooperation partners here: (List will be continued.)
|
|
|
|
Follow iMyoS on Instagram
|
|
|
|
|
|
|
|
|
